Phase I-IIa Facilities
Frontage Hackensack, NJ, Clinical Research Center
Our 72-bed, state-of-the-art Clinical Research Center is located in Hackensack, NJ, within 15 miles of New York City. The Frontage facility is situated in an ethnically and socioeconomically diverse region, close to a major medical center and within easy traveling distance of major airports and other transportation. Among the trials we perform are:
- First-in-human
- Dose escalation
- Repeated dose
- Proof-of-concept
- Pharmacokinetic
- Pharmacodynamic
- Bioavailability
- Bioequivalence
- Fed-fasted
Drug-drug and drug-alcohol interactions
Frontage also has significant experience performing studies in targeted patient populations, such as those for cardiovascular, metabolic, osteoarthritic, urologic and dermatologic disorders, as well as studies involving pre- and post-menopausal women, men and women with obesity and metabolic syndrome and men with low testosterone.
Frontage Zhengzhou, China, Clinical Research Center
Our 130-bed, hospital-based Clinical Research Center is located in Zhengzhou, China, approximately a one-hour flight from Beijing. The Frontage Clinical Research Center was opened in 2009 and resides in the First Affiliated Hospital of Zhengzhou University, a 6,000-bed facility that is considered one of the top hospitals in China.
Frontage’s China Clinical Research Center operates under the same standard operating procedures as the Clinical Research Center in the United States. Additionally, the research staff and leadership team have all received their training in the United States. The capabilities of the China Clinical Research Center include:
- First-in-human
- Dose escalation
- Proof-of-concept
- Bioavailability
- Bioequivalence
- Pharmacokinetic
- Pharmacodynamic
- Fed-fasted
- Drug-drug and drug-alcohol interactions
